Don’t be surprised to see pharma seek to change the US patent reform debate
Washington DC is in mid-term election mode and, as it’s not clear how the battle for control of the Senate will play out, speculating on what is going to be on the next Congress’s agenda might be regarded as a little foolish. So, I thought I’d give…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.